Literature DB >> 22621697

MicroRNAs in the pathogenesis of malignant melanoma.

M Glud1, R Gniadecki.   

Abstract

Cutaneous malignant melanoma is the most aggressive and lethal form of skin cancer. Over the past decades, its incidence has been increasing by 3-8% per year in western countries while mortality has stabilized. Melanoma is a heterogenous disease and can be subclassified based on distinct clinical characteristics, histopathological features and mutation patterns within NRAS and BRAF genes. Recent data indicate that microRNAs (miRNAs) are involved in the pathogenesis of malignant melanoma. MiRNAs are small, non-coding, regulatory RNA molecules expressed in a tissue and cell specific manner and are known to play a crucial role in cell homeostasis and carcinogenesis. MiRNAs might prove to be powerful cancer biomarkers and future therapeutic targets. In this review, we focused on the miRNA involvement in four molecular pathways known to be deregulated in malignant melanoma, including the RAS-RAF-MEK-ERK pathway, the p16(INK4A) -CDK4-RB pathway, the PIK3-AKT pathway and the MITF pathway.
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621697     DOI: 10.1111/j.1468-3083.2012.04579.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  10 in total

1.  Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry.

Authors:  Beatriz Sánchez-Sendra; Silvia Pérez-Debén; José F González-Muñoz; Amelia Murgui; Carlos Monteagudo
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

Review 2.  miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Authors:  Paige E Bennett; Lynne Bemis; David A Norris; Yiqun G Shellman
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

3.  MicroRNA-211 Loss Promotes Metabolic Vulnerability and BRAF Inhibitor Sensitivity in Melanoma.

Authors:  Anupama Sahoo; Sanjaya K Sahoo; Piyush Joshi; Bongyong Lee; Ranjan J Perera
Journal:  J Invest Dermatol       Date:  2018-08-01       Impact factor: 8.551

4.  There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis.

Authors:  Rolf K Swoboda; Meenhard Herlyn
Journal:  Exp Dermatol       Date:  2013-03-12       Impact factor: 3.960

5.  Identification of epigenetically altered genes and potential gene targets in melanoma using bioinformatic methods.

Authors:  Honghao Duan; Ke Jiang; Dengke Wei; Lijun Zhang; Deliang Cheng; Min Lv; Yuben Xu; Aimin He
Journal:  Onco Targets Ther       Date:  2017-12-20       Impact factor: 4.147

Review 6.  Long non-coding RNAs in cutaneous melanoma: clinical perspectives.

Authors:  Eva Hulstaert; Lieve Brochez; Pieter-Jan Volders; Jo Vandesompele; Pieter Mestdagh
Journal:  Oncotarget       Date:  2017-06-27

7.  Reciprocal Changes in miRNA Expression with Pigmentation and Decreased Proliferation Induced in Mouse B16F1 Melanoma Cells by L-Tyrosine and 5-Bromo-2'-Deoxyuridine.

Authors:  Hernán Mauricio Rivera; Esther Natalia Muñoz; Daniel Osuna; Mauro Florez; Michael Carvajal; Luis Alberto Gómez
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 8.  The Human Microbiota and Skin Cancer.

Authors:  Yu Ri Woo; Sang Hyun Cho; Jeong Deuk Lee; Hei Sung Kim
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

9.  New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion.

Authors:  Christiane Margue; Demetra Philippidou; Susanne E Reinsbach; Martina Schmitt; Iris Behrmann; Stephanie Kreis
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

10.  Downregulation of intratumoral expression of miR-205, miR-200c and miR-125b in primary human cutaneous melanomas predicts shorter survival.

Authors:  Beatriz Sánchez-Sendra; Carolina Martinez-Ciarpaglini; José F González-Muñoz; Amelia Murgui; Liria Terrádez; Carlos Monteagudo
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.